. Structure of Aberrant EAAT2 mRNA in ALS (A) Schematic presentation of abnormally processed partial intron 7-retention and exon 9-skipping species in relation to the normal EAAT2 gene. Numbered boxes represent individual exons. The connected arrow heads indicate the primer regions used for RT-PCR. The hatched bars indicate the regions used to prepare probes for in situ hybridization. Probe E corresponds to position 1687-2210 from the 5Ј translation region. Probe F corresponds to position 537-1008 from the exon 7 intron junction. The triangle indicates a Hind III site used as an insertion site for constructing an internal control plasmid pE2F. abnormal cDNA clone was subsequently identified from which was amplified along with the normal-size PCR fragment in the patient but was not present in normal positive clones by restriction analysis. Sequencing of this clone revealed that it contained 1091 bp of the controls ( Figure 2A ; at exon 9-skipping EAAT2; ALS patient 2). The shorter PCR fragment was cloned. DNA EAAT2 coding region from exon 1 to exon 7, followed by 1008 bp of intron region, corresponding to partial sequencing revealed it to be a 135 bp in-frame deletion in which exon 8 is linked directly to exon 10, demonstratsequence of intron 7, ending with a poly A tail (Aoki et al., 1998; Figure 1A) . A stop codon was found immediing that it arises from skipping exon 9 (Aoki et al., 1998 ; Figure 1A ). ately after this exon and intron junction. Thus, the presumed translation product would be EAAT2 protein trunFurthermore, when primers D and C ( Figure 1A ) were used to amplify the full-length EAAT2 coding region, a cated after codon 364.
To ensure that this was not a cloning artifact, reverselarge amount of shorter PCR fragments was observed in motor cortex of ALS but not in normal controls (Figure transcription polymerase chain reaction (RT-PCR), with the use of a primer pair that included normal exonic and 2C). All of the shorter PCR fragments from ALS patient 3 ( Figure 2C ) were then cloned. Twenty clones were intronic sequences ( Figure 1A , primers A and B), was performed on equal amounts of poly (A) ϩ mRNA (DNase randomly selected and analyzed by restriction digestion. All of the these clones were found to have different I treated) prepared from motor cortex of the ALS patient and normal controls. As shown in Figure 2A (at introninternal deletions. In addition, a single band from the gel (Patient 3, Figure 2C ) was cloned and was found to retention EAAT2; ALS patient 3), a strong signal was observed in the ALS specimen but not in the control consist of multiple internally deleted cDNA, all similar in size. These results indicate that there are many different specimens.
As another approach, we also used RT-PCR to amplify truncated EAAT2 transcripts in ALS motor cortex. Eight of the truncated cDNAs were then sequenced EAAT2 cDNA fragments from poly(A) ϩ mRNA prepared from the spinal cord or motor cortex of the patient and at the junction of the deletion regions ( Figure 1B ). Two cDNAs were found to be truncated due to exon-skipping from normal controls. A shorter PCR fragment was subsequently identified, using primers A and C ( Figure 1A) , (Figures 1B 7 and 1B 8 appropriate splicing donor and acceptor sites (Figure Thus, several observations suggest that these aberrant RNA species were specific for ALS and were not 1B5). Other truncated cDNAs were identified, although the deletions did not occur at common splicing sites an artifact. They were not observed in other neurodegenerative disorders, including Huntington's disease, Alz-( Figures 1B1-1B4 and 1B6 ). The presence of multiple precise exon-skipping deletions ( Figures 1A and 1B) sugheimer's disease, and spinal muscular atrophy; they were found only in neuropathologically affected brain gests that it is very unlikely that they could be caused by somatic DNA deletions. The abundance of multiple regions, while unaffected brain regions in the same patients had normal EAAT2 RNA. Other transporter protruncated transcripts may be the result of aberrant RNA splicing.
teins, as well as constitutive RNA species, were not affected. To examine the specificity of these defects for brain region and transporter subtypes, ALS and control tissue from several brain regions in the same patient were
The Aberrant EAAT2 Transcripts Are Present In Vivo examined. As shown in Figure 2C , multiple truncated EAAT2 mRNAs were found in ALS motor cortex but not To verify that these aberrant EAAT2 transcripts were present in vivo and not a cloning or PCR artifact, in cerebellum or hippocampus from the same patient (3). Similar results were obtained from every ALS patient situ hybridization was performed to detect partial intron 7-retention mRNA using a riboprobe to the intronic reexamined (n ϭ 20). Other cell-specific and general cellular mRNA species were examined. Truncated transcripts gion ( Figure 1A , probe F). Figures 3A and 3B show that this partial intron 7-retention mRNA was present only were not found for the astroglial glutamate transporter EAAT1 ( Figure 2D ), the neuronal protein EAAT3, or the in ALS motor cortex, but not in control specimens, in agreement with the RT-PCR results. In addition, signals constitutive spliceosomal assembly protein (the survival motor neuron [SMN] ) Liu et al., were uniformly localized to small cells, presumably astrocytes, present throughout the motor cortex (EAAT2 1997; Figure 2D ). EAAT1 and EAAT3 protein levels were previously shown to be normal in ALS (Rothstein et al., is an astrocyte-specific protein) ( Figure 3D , asterisk). As a control, signals for actin ( Figures 3C and 3F ) were 1995). The partial intron 7-retention mRNA was localized to small cells throughout the motor cortex in ALS (A) but was not detected in control motor cortex (B). When compared to mRNA for the general cellular protein actin (C), the localization appeared to be consistent with astrocytes. Higher power analysis ([D] , [E] , and [F]) of ALS motor cortex confirmed that aberrant partial intron 7-retention mRNA was localized to small cortical cells ([D] , asterisk), identical to the localization of wild-type EAAT2 mRNA in ALS cortical astrocytes (E), whereas actin was localized in both astrocytes and neurons ([F] , arrow) in ALS motor cortex. The localization of the partial intron 7-retention EAAT2 mRNA (A) correlated with the decreased expression of EAAT2 protein (G) in ALS compared with expression of EAAT2 protein in control motor (H) cortex. Immunohistochemistry and in situ hybridization studies were performed on three different specimens. Scale bar, 0.1 mm for (A), (B), (C), (G), and (H); 0.01 for (D), (E), and (F).
found to be expressed by both neurons (arrowhead) and provides evidence that these aberrant splicing EAAT2 transcripts were present in vivo. Northern analysis of astroglia. Wild-type EAAT2 mRNA in ALS ( Figure 3E ) and in control tissue (data not shown) was expressed EAAT2 mRNA could not be used for this purpose because the size of normal EAAT2 mRNA is about 11 kb in a distribution similar to the partial intron 7-retention mRNA. No staining was seen with sense controls (data and the truncated transcript would only be ‫2-1ف‬ kb smaller. Therefore, it would be difficult to identify these not shown). Furthermore, the dramatic loss of EAAT2 protein (Rothstein et al., 1995; Figures 3G and 3H) in truncated transcripts from full length transcript using this method. ALS motor cortex appears to be associated with the presence of the partial intron 7-retention transcripts, which was specific to ALS and was not detected in Up to 70% of Total EAAT2 Transcripts Are Aberrant RNA Processing Products motor cortex from control specimens ( Figure 3B ) or in specimens of motor cortex from ALS patients that were
To determine the abundance of the aberrant mRNA species relative to wild-type EAAT2, we performed quantitanot RT-PCR-positive for the intron-retention transcripts (data not shown). Finally, S1 nuclease protection analytive RT-PCR using mRNA from ALS patient 4. This patient was chosen because RT-PCR studies revealed only sis of EAAT2 mRNA ( Figure 4C ; described below) also mRNA from ALS patient 4. PCR reaction products from different amplification cycles were subjected to Southern blot analysis using an oligonucleotide probe located at the 3Ј end of the PCR fragment. Abbreviations: wt, wild-type EAAT2; tr-1 and tr-2, two truncated aberrant species. (B) The amounts of radioactivity recovered from the excised membrane bands in (A) were plotted as a function of the number of cycles. The rates of amplification were exponential between 14 and 24 cycles for full length and truncated templates. More than 70% of total EAAT2 mRNA is in the form of aberrant transcripts. (C) S1 nuclease protection analysis of EAAT2 mRNA using a 836 base single strand DNA probe, located at the 3Ј end of the coding region. A schematic representation of the probe, the wild-type mRNA, and the aberrantly spliced mRNA (tr-2) are shown on the right. The protection fragments were subjected to Southern blot analysis using an oligonucleotide probe located at the 3Ј end of the protection fragment. As with quantitative RT-PCR, the abnormal species were abundant in the ALS specimens compared to normal EAAT2.
two types of truncated transcripts ( Figure 2C ). PCR reacprotection fragments, which is in agreement with the quantitative RT-PCR results ( Figure 4B ). tion products from different amplification cycles were resolved by gel electrophoresis and transferred to membrane for Southern blot analysis ( Figure 4A ). The amount Aberrant EAAT2 Transcripts Are Commonly Present in Sporadic ALS and They Are Correlated of radioactivity recovered from the excised membrane bands was plotted as a function of the number of cycles with Loss of EAAT2 Protein To evaluate the prevalence of these aberrant EAAT2 ( Figure 4B ). The rates of amplification were exponential between 14 and 24 cycles for full-length and truncated transcripts in ALS, 30 ALS specimens were screened, including spinal cord, motor cortex, and cerebellum, for templates. The results revealed that full-length (wildtype) and truncated transcripts tr-1 and tr-2 represent partial intron 7-retention and exon 9-skipping transcripts by competitive RT-PCR ( Figure 2A ). An internal 28%, 2%, and 70% of total EAAT2 transcript, respectively. It is notable that the truncated transcript tr-2 from control was designed to amplify along with the partial intron 7-retention mRNA ( Figure 1A ; see Experimental this patient is the same as the transcript in Figure 1B 7 . As described below, this truncated transcript produced Procedures). Since the exon 9-skipping mRNA was 135 bp shorter than the wild-type EAAT2 mRNA, the wilddownregulation of normal EAAT2 in vitro.
We also performed S1 nuclease protection assays to type EAAT2 mRNA was used as an internal control for the comparative analysis of the exon 9-skipping mRNA evaluate the relative abundance of the aberrant mRNA species. A 836 base single-strand DNA probe located between patients. All RT-PCR experiments were repeated 2-5 times for each specimen to verify the presat the 3Ј end of the coding region was used. The S1 nuclease-resistant fragments were resolved by gel elecence of aberrant mRNA species. Both aberrant transcripts were commonly found; 20 of the 30 ALS patients trophoresis and transferred to membrane. The blot was probed with an oligonucleotide probe located at the 3Ј had the partial intron 7-retention mRNA and 11 of the 30 ALS patients had the exon 9-skipping mRNA. These end of the protection fragment. As shown in Figure 4C , large amounts of Ͻ836 bp S1 nuclease-resistant fragaberrant mRNA species were found only in ALS motor cortex, or spinal cord, or both, but not in cerebellum. ments were observed in ALS specimens but were not seen in the control specimens. The mRNA sample from
To determine the disease specificity of these aberrant mRNA species, other nonneurological and neurological ALS patient 4 used in this experiment was the same one used for quantitative RT-PCR described above. The 346 disease control tissues were examined (Table 1) , including tissue from neuropathologically affected and unafbp S1 nuclease-resistant fragment, corresponding to the truncated transcript tr-2, represents 73% of the total fected regions. The aberrant mRNA species were not found in any of the neural tissues from a total of 48 dementia. The exon 9-skipping mRNA was not detected in the 38 control specimens but was detected in 12 out controls, including 27 nonneurological disease control specimens (12 spinal cord and 27 motor cortex), 8 spinal of 18 (66%) ALS specimens. In addition, in four ALS cases (Table 2) , CSF obtained during diagnostic evaluamuscular atrophy specimens (SMA-type 1) (spinal cord), 7 Alzheimer's disease specimens (7 hippocampus and tion and brain tissue obtained at autopsy were available from the same patients. In those patients, CSF was col-7 motor cortex), and 6 Huntington's disease specimens (6 caudate and 6 motor cortex). The control tissues were lected 25.5 Ϯ 6 (SEM) months prior to death. In all cases, the presence of the exon 9-skipping mRNA was dematched for age and postmortem delay ( Table 1) .
The presence of abnormal mRNA was significantly tected in both antemortem CSF and postmortem brain or spinal cord tissue. (p Ͻ 0.001) correlated with the loss of EAAT2 protein. ALS specimens from motor cortex or spinal cord that had very low levels of EAAT2 protein (Ͻ30% of control)
Proteins Translated from These Aberrant Transcripts Are Unstable and/or Cause Downregulation contained both partial intron 7-retention and exon 9-skipping transcripts ( Figure 5A ). Eight out of 30 ALS patients of Normal EAAT2 In Vitro To determine if proteins translated from these aberrant had both partial intron 7-retention and exon 9-skipping mRNA. An intermediate loss of EAAT2 protein in neural EAAT2 transcripts could be identified in the ALS postmortem tissue, we analyzed ALS motor cortex for a cartissue, 30%-80% of control levels, was associated with the presence of the partial intron 7-retention mRNA boxy-terminal truncated EAAT2 protein (the presumed protein product of the partial intron 7-retention tranalone. In addition, the loss of EAAT2 protein was inversely correlated with the amounts of either the exon script) by Western blotting with amino-terminal oligopeptide antibodies to human EAAT2 protein (Rothstein 9-skipping (rs ϭ 0.81, p Ͻ 0.001) or the partial intron 7-retention mRNA (rs ϭ 0.62, p Ͻ 0.001; Figure 5B) . et al., 1995) . Previous studies have shown that the amino-terminal antibody can recognize wild-type EAAT2 Although the presence of aberrant mRNA species appeared to correlate with a loss of protein, rarely did in human tissue. However, using this antibody, no immunoreactive band with the expected size of the truncated patients with a loss of EAAT2 not have either of these aberrant mRNA. In those cases, the loss of protein could EAAT2 protein was detected. The protein from the exon 9-skipping transcript was also investigated in ALS tisbe due to other as yet unidentified variants in EAAT2 mRNA. Alternatively, other mechanisms known to lead sue, using oligopeptide antibodies to the amino acid sequence spanning the deletion site. Again, no immunoto degradation of glutamate transporter proteins, e.g., oxidative stress, could have resulted in a loss of EAAT2 reactive band was detected (data not shown). The inability to detect the aberrant EAAT2 proteins could be due (Volterra et al., 1994; Trotti et al., 1996) .
The presence of the aberrant mRNA species did not to several possibilities: (1) the aberrant EAAT2 proteins could be very unstable or rapidly degraded in postmortem correlate with the clinical presentation (spinal versus bulbar onset) of the disease in ALS patients. ALS patissue, or both, or (2) the aberrant proteins may not be detectable with the available antibodies, or (3) the abertients with altered EAAT2 mRNA species had a tendency toward shorter survival (17 Ϯ 2.9 [SEM] months) when rant proteins may also affect normal EAAT2 function.
To evaluate the properties of these abnormal trancompared to the overall average for ALS of 2-5 years but not when compared to the ALS scripts, EAAT2 cDNA was transiently expressed in COS7 cells. EAAT2 protein was quantitated 72 hr postpatients in this study without aberrant mRNA species (23 Ϯ 4.8 [SEM] months).
transfection by Western blotting, and activity of the transporter was measured by a sodium-dependent 3 Hglutamate transport assay (Rothstein et al., , 1995 .
Detection of Aberrant EAAT2 Transcripts in Cerebrospinal Fluid
Wild-type EAAT2 protein was detected by a carboxyterminal EAAT2 antibody ( Figure 6A , lane 1) as well as Cerebrospinal fluid (CSF) was also examined for the presence of the exon 9-skipping transcript in ALS and evidence of glutamate transport. Wild-type EAAT2 was not detected by the available amino-terminal antibody. control specimens ( Figure 2B ). All specimens were processed identically. Control CSF was obtained from paAs expected, predicted truncated protein synthesized from the partial intron 7-retention cDNA was not detients with neurological diagnoses that included multiple sclerosis, normal pressure hydrocephalus, hepatic entected by this carboxy-terminal antibody ( Figure 6A , lane 5). Nevertheless, there was evidence that the partial cephalopathy, migraine headache, subarachnoid hemorrhage, stroke, epilepsy, ataxia, CNS vasculitis, and intron 7-retention EAAT2 cDNA was expressed by the COS7 cells, because the partial intron 7-retention mRNA ( Figure 6A , lanes 2-4). The same results were obtained when the partial intron 7-retention cDNA was coexpressed was detected in the transfected cells by Northern blotting and RT-PCR (data not shown). No glutamate transin HeLa cells ( Figure 6A , lanes 6-7). These coexpression studies suggest that the partial intron 7-retention cDNA port was observed in COS7 cells transfected with the partial intron 7-retention cDNA.
could dominantly downregulate EAAT2 protein. This effect was specific for EAAT2; coexpression of the intronWhen the partial intron 7-retention cDNA was cotransfected with the normal EAAT2 cDNA into COS7 cells, retention cDNA with wild-type EAAT1, EAAT3, or EAAT4 cDNA had no effect on either the astroglial subtype there was a progressive decrease in the level of normal EAAT2 protein ( Figure 6A, lanes 2-4) . However, the lev-EAAT1 ( Figure 6A , lanes 8 and 9) or the neuronal subtypes EAAT3 and EAAT4 (data not shown) protein or els of wild-type EAAT2 mRNA, using Northern analysis, were not decreased by the partial intron 7-retention glutamate transport. This effect is not due to the promoter competition between wild-type and partial intron cDNA ( Figure 6A, lanes 2-4) . Glutamate transport also decreased in parallel with the loss of EAAT2 protein 7-retention cDNA because (1) the levels of wild-type H-glutamate transport assay. (A) The partial intron 7-retention EAAT2 cDNA produced a negative effect on the normal EAAT2 protein level and glutamate transport (paradigms 1-7) but had no effect on EAAT2 mRNA levels (paradigms 1-5), EAAT1 protein levels (paradigms 8 and 9), or EAAT1 glutamate transport (paradigms 8 and 9). (B) The exon 9-skipping EAAT2 species had no effect on EAAT2 protein expression (paradigm 3) or on wild-type glutamate transport (paradigm 3). All aberrant or wild-type EAAT2 (EAAT1) cDNAs were in the same vector (pcDNA3).
EAAT2 mRNA were not decreased and (2) this effect cells. Expression of fusion proteins was examined by Western blotting using anti-GFP antibodies ( Figure 7A ). was not observed in other subtypes of glutamate transporters with the same vector and transfection condiBoth the partial intron 7-retention ( Figure 7A , lane 3) and the exon 9-skipping ( Figure 7A , lane 4) EAAT2-tions.
The exon 9-skipping EAAT2 cDNA was also ex-GFP proteins were expressed at the expected lower molecular weights. Furthermore, the mutant EAAT2-pressed in COS7 cells. Although the protein was not detected by Western blotting ( Figure 6B, lane 2) , the GFPs appeared to be unstable compared to the wildtype EAAT2-GFP ( Figure 7A , lane 2), as judged by the mRNA was detected in the transfected COS7 cells by RT-PCR. However, no glutamate transport was obpresence of less protein and multiple lower molecular weight species ( Figure 7A, lanes 3 and 4) . served in the transfected COS7 cells by sodium-dependent 3 H-glutamate transport assay. Notably, in this para-
The cellular localization of the fusion proteins was then examined by fluorescent microscopy. Wild-type EAAT2-digm, the exon 9-skipping cDNA had no effect on the expression of wild-type EAAT2 protein or glutamate GFP was preferentially localized to the cell surface (Figure 7B) . However, both the partial intron 7-retention and transport ( Figure 6B, lane 3) .
To confirm that the aberrant EAAT2 cDNAs were exthe exon 9-skipping EAAT2-GFP fusion proteins were restricted to the cytoplasm, were often peri-nuclear (Figpressed and translated, we constructed chimeric genes to encode C-terminal fusions of wild-type or mutant ure 7B), and were found occasionally in lysosomes (data not shown). When wild-type EAAT2-GFP was coex-EAAT2 to green-fluorescent protein (GFP). These constructs were expressed in COS7 cells and all produced pressed with the partial intron 7-retention EAAT2 (not GFP-labeled), the wild-type protein was found largely similar levels of mRNA by Northern blotting (data not shown). The wild-type EAAT2-GFP-transfected cells confined to the cytoplasm, with occasional cell membrane staining ( Figure 7B ). The same results were obhad normal 3 H-glutamate transport activity (data not shown) when compared to non-GFP EAAT2-transfected served from coexpression of partial intron 7-retention (B) Visualization of normal and aberrant EAAT2 protein in COS7 cells. COS7 cells expressing GFP, wild-type EAAT2-GFP, partial intron 7-retention EAAT2-GFP, or exon 9-skipping EAAT2-GFP proteins were examined by fluorescent microscopy. Aberrant proteins (exon-9 skipping-GFP, partial intron 7-retention-GFP expressed alone or with wild-type EAAT2) were largely confined to the cytoplasm, compared to normal surface membrane localization of EAAT2. A coexpression of the GFP-labeled EAAT2 with the unlabeled partial-intron 7-retention EAAT2 revealed that the aberrant protein interfered with the localization of wild-type protein in the surface membrane. Magnification, 400ϫ. All transfection experiments were repeated five times in triplicate.
3 H-glutamate transport is expressed as mean transport Ϯ SEM compared to control.
EAAT2-GFP with wild-type EAAT2 (not GFP-labeled)
protein was localized on the cell surface when expressed alone or with the exon-9 skipping EAAT2 ( Figure  (Figure 7B ). These results suggest that the partial intron 7-retention EAAT2 protein may interfere with normal 7B), and (3) the partial intron 7-retention EAAT2 (not GFP-labeled) still interfered with the wild-type EAAT2 EAAT2 protein complex assembly or trafficking. These results were not seen with the exon-9 skipping EAAT2, protein trafficking to the cell membrane. Eight other aberrant cDNAs were also expressed (dewhich did not interfere with wild-type EAAT2 localization ( Figure 7B) . Importantly, the abnormal protein localizascribed in Figure 1B ) in COS7 cells. Two of them, shown at Figures 1B 4 and 1B 7 , also showed a dominant downtion is probably not due to the influence of the GFP fusion because (1) wild-type EAAT2-GFP-transfected regulation effect on normal EAAT2 activity and protein expression like the partial intron 7-retention EAAT2 cells had normal glutamate uptake, (2) the wild-type GFP cDNA, whereas the remaining cDNAs were unstable and with retinoic acid receptors, ultimately dominantly downregulating vitamin D signaling (Ebihara et al., 1996) . inactive like the exon 9-skipping EAAT2 cDNA.
Can Aberrant EAAT2 mRNA Contribute to Motor Neuron Degeneration? Discussion
Interestingly, the aberrant EAAT2 mRNAs were restricted to motor cortex and spinal cord, the primary Loss of EAAT2 Protein in ALS Is Due to Aberrant EAAT2 Transcripts regions of neurodegeneration. Because ALS is characterized by the death of motor neurons, it is possible that Functional glutamate transport is deficient in ALS, and a substantial proportion of patients with sporadic disease these aberrant EAAT2 transcripts are secondary to a motor neuron degeneration, or an astrocyte response have a large loss of the EAAT2 glutamate transporter protein. In this study, our results provide evidence that to neuronal degeneration, or both. We did not find a loss of EAAT2 or the presence of aberrant EAAT2 mRNA the loss of EAAT2 protein in ALS may be due to aberrant EAAT2 mRNA, possibly as a consequence of abnormal species in a subset of ALS patients, all of whom had pathological confirmation of motor neuron loss. Neither RNA splicing. The evidence for this conclusion includes the following. (1) The aberrant EAAT2 transcripts were were they found in other neurodegenerative diseases, such as SMA, Alzheimer's, or Huntington's diseases, found only in ALS motor cortex and spinal cord-the only regions where there was a concomitant loss of which are also characterized by slow loss of neurons (including motor neurons) and astrogliosis. Similarly, the EAAT2 protein (Figure 2) . (2) In situ hybridization studies indicated that loss of EAAT2 protein (Rothstein et al., partial intron 7-retention and the exon-9 skipping EAAT2 mRNA were not found in transgenic mice carrying a 1995) in ALS motor cortex appeared to be associated with the presence of the aberrant EAAT2 transcripts in familial ALS SOD1 mutation (G37R) (unpublished data). The aberrant mRNA species were also detected in pavivo (Figure 3) . (3) S1 nuclease protection assay and quantitative RT-PCR revealed that, in ALS specimens tient CSF up to 4 years prior to death. Thus, the aberrant mRNA species are not likely to be simply a result of with low EAAT2 protein, the majority of EAAT2 mRNA was in the form of aberrant splicing products (Figure 4) . motor neuron loss or postmortem artifact. Antisense knockdown studies demonstrate that loss (4) Screening studies revealed that the aberrant EAAT2 mRNA is commonly present in sporadic ALS patients.
of EAAT2 can lead to excitotoxic neuronal degeneration and a progressive syndrome of motor impairment About 65% of all postmortem specimens have one or both of the partial intron 7-retention and exon 9-skip- . EAAT2 null mice also develop excitotoxic neuronal degeneration (Tanaka et al., 1997) . ping transcripts. The relative quantity of these abnormal EAAT2 mRNAs correlated with the degree of EAAT2 Thus, even if aberrant EAAT2 transcripts are due to an astrocyte response to neuronal degeneration or other protein loss in ALS tissue ( Figure 5 ). (5) Studies of CSF from living patients also independently confirmed their factors, the subsequent loss of EAAT2 could act to propagate motor neuron degeneration in ALS. The clinical specific association with ALS ( Figure 2B ). (6) And finally, in vitro expression studies suggested that proteins efficacy of anti-glutamate drugs in ALS and transgenic models of ALS (Bensimon et al., 1994; , translated from these aberrant EAAT2 mRNAs may undergo rapid degradation and produce, in vitro, a domi-1996; Lacomblez et al., 1996) support the notion that glutamate-mediated toxicity, in part due to the loss of nant negative effect on normal EAAT2 resulting in loss of protein and activity (Figures 6 and 7) . Taken together, EAAT2, could contribute to the pathogenesis of ALS. these studies suggest that the presence of the aberrant EAAT2 mRNA may directly relate to the loss of EAAT2
What Is the Origin of the Aberrant protein commonly found in sporadic ALS.
EAAT2 Transcripts?
The origin of the abnormal mRNA has not been determined, but one can speculate on several possible mechHow Does Mutant Protein Dominantly Downregulate Normal EAAT2 Protein?
anisms. It could result from relaxation of RNA processing fidelity or an abnormality in the pathway for degradation The mechanism by which the mutant proteins interfere with wild-type EAAT2 activity is not known. Little is of mutant mRNA. In C. elegans, smg genes appear to participate in the degradation of some, but not all, muknown about glutamate transporter membrane organization or trafficking. Limited data suggests that under tant mRNAs (Morrison et al., 1997) . The presence of multiple aberrant EAAT2 mRNAs strongly suggests ponormal conditions, EAAT2 monomers may self-associate to form homomeric multimers in vivo (Haugeto et tential defects in RNA processing. Oxidative stress could damage DNA encoding RNA processing proteins al., 1996). It may be that the heteromers composed of mutant truncated EAAT2 and wild-type EAAT2 protein or could damage the proteins responsible for RNA processing. Damaged RNA processing proteins could lead subunits undergo rapid degradation, as suggested by our studies. This could explain the loss of EAAT2 in to relaxation of RNA processing fidelity, which may contribute to abnormal gene expression. Interestingly, SMN, COS7 cell expression experiments and in ALS, although other processes may be responsible. Examples of such the gene responsible for spinal muscular atrophy, another motor neuron disease, has been found to code dominant-negative interactions between multimeric proteins is not uncommon. For example, a retained intron for a protein that is a newly described component of the RNA processing complex (Fischer et al., 1997; Liu for the vitamin D receptor leads to a truncated protein in mice. This protein subsequently forms heterodimers et al. , 1997) . SMN protein appears to part of a protein complex responsible for the assembly of common small be due to aberrant EAAT2 transcripts. Disorders of RNA processing, either as a primary defect as in spinal musnuclear ribonucleoproteins, and as such may participate in the actions of RNA processing. Loss of SMN in spinal cular atrophy or secondary to other cellular defects, could be important mechanisms for neurodegenerative muscular atrophy can be lethal and causes motor neuron degeneration, perhaps because of interference with disease. Ultimately, identification of the events that lead to aberrant RNA processing could provide an opportu-RNA processing. There may be acquired damage to RNA processing proteins, such as SMN protein, which nity for the development of specific therapies designed to prevent the loss of glutamate transport in ALS. The subsequently leads to aberrant splicing of EAAT2 in affected ALS brain regions. Because abnormal pre-RNA observation that these aberrant EAAT2 mRNA species are commonly present in sporadic ALS and can be deprocessing may be a cause of spinal muscular atrophy, a future evaluation of EAAT2 RNA in SMA would be tected in the CSF of ALS patients may also provide an important tool for development of a sensitive test for interesting.
If these aberrant mRNA species are due to a regionearly diagnosis of the fatal disease, allowing for early initiation of treatments designed to prolong survival. or cell-specific defect in RNA processing, then other aberrantly processed RNA species may be discovered in future studies. EAAT1 is the other astroglial glutamate
Experimental Procedures
transporter and has a genomic structure similar to Tissue and CSF Specimens EAAT2 (Hagiwara et al., 1996; Stoffel et al., 1996; Meyer have been found to result in exon-skipping and intronneuron loss, and with myelin stains (Luxol-fast blue) to establish corticospinal tract degeneration. SOD1 mutation analysis was perretention (Kuivenhoven et al., 1996; Sakai et al., 1996;  formed by R. H. Brown, Harvard University. Pathologically confirmed Wang et al., 1996) . In some disorders, such as cholesAlzheimer's disease and Huntington's disease brain tissue was proteryl ester transfer protein deficiency (Sakai et al., 1996) , vided by the Johns Hopkins Alzheimer's Disease Research Center intronic mutations can be distant from the intronic retenBrain Bank. SMA spinal tissue was obtained at autopsy from patients tion, or the exon-skipping regions of the processed RNA, diagnosed by one of us (T.C.). CSF was obtained at the time of or both. However, a recent extensive study of EAAT2 diagnostic evaluation for ALS and control patients with institutionapproved informed consent. CSF was rapidly frozen and stored at exon-intron splice sites in sporadic and familial ALS did Ϫ20ЊC to Ϫ70ЊC for up to 6 years. not reveal the presence of mutations, ruling out intraThe clinical diagnosis of ALS was made by the El Escorial criteria genic DNA mutations of EAAT2 as a cause of the aber- (Brooks, 1994) , including the presence of both upper and lower rant mRNA species in our study (Aoki et al., 1998 (Bowling et al., 1993; Borthwick et al., 1996; Beal et al., elopathy, or peripheral neuropathy. 1997; Ferrante et al., 1997a Ferrante et al., , 1997b . Oxidative stress could damage DNA encoding EAAT2 or could damage Immunoblot the proteins responsible for DNA repair and eventually Immunoblots were performed as described previously (Rothstein et al., 1995) on 4-25 g of crude homogenate from motor cortex or lead to somatic alterations of EAAT2. Significantly, loss from homogenized transfected COS7 cells grown on 75 mm plastic of EAAT2 can cause excitotoxic neuronal (including moculture plates (CoStar), with affinity-purified polyclonal antibodies tor neuron) degeneration , and to the carboxyl-terminal region of EAAT2 (Rothstein et al., 1995) or excitotoxicity can induce generation of free radicals and to green fluorescent protein (GFP) (1:2000; Clontech). Glutamate DNA damage (Campagne et al., 1995; Didier et al., 1996) . transport was measured as described (Rothstein et al., 1992) except Accumulating evidence suggests that ALS, the protousing intact COS7 cells grown on 30 mm, six-well plates (CoStar).
typical motor neuron disease, may have multiple different pathogeneses. Furthermore, primary defects (e.g.,
EAAT2
Cloning Poly (A) mRNA was isolated using the FastTrack 2.0 mRNA isolation SOD1 mutations) may initiate a cascade of secondary, kit (Invitrogen). cDNA was synthesized from the isolated mRNA by but potent, toxic events in the nervous system that are using ZAP express cDNA synthesis kit (Stratagene). The cDNA was ultimately responsible for motor neuron degeneration.
size fractionated into three fractions, Ͼ6 kb, 3-6 kb, and Ͻ3 kb, by Loss of EAAT2 protein is a potent toxic event because GCCACCACTCT-3Ј) corresponding to position Ϫ428. Primers used for RT-PCR of EAAT1 were as follows: 5Ј-AGGAGGTTTGGCTTTCTG TGG-3Ј corresponding to position Ϫ73; 5Ј-GGTTTTTAACACCTGGT RT-PCR GCTCAA-3Ј corresponding to position 1655 from the 5Ј translation Poly(A) mRNA was isolated from 50-100 mg of specimens (motor region. Primers used for RT-RCR of SMN were as follows: 5Ј-cortex, frontal cortex, hippocampus, caudate, cerebellum, and lum-GCGGGTTTGCTATGGCGATGA-3Ј corresponding to position Ϫ11; bar or cervical spinal cord) by using Micro-Fast Track Kit (Invitrogen).
5Ј-CAGCCATGTCCACCAGTTAGA-3Ј corresponding to position 1398 The isolated mRNA was treated with DNase I for 20 min, heated to from the 5Ј trasnslation region. Oligonucleotides used for preparing 65ЊC for 5 min, and then reverse transcribed into cDNA. A 25 l probes were as follows: 5Ј-CGGCTGACTTTCCATTGGCTG-3Ј correreverse-transcription reaction mixture containing 50 ng of mRNA, 1 sponding to position 1664 from the 5Ј translation region of EAAT2; mM dithiothreitol, 0.5 mM dNTPs, 20 units of RNasin, 200 units of 5Ј-CCTGGTGCTCAAGAAAGTGTTTC-3Ј corresponding to position M-MLV reverse transcriptase (BRL), 1ϫ buffer, and 0.5 M primer 1664 from the 5Ј translation region of EAAT1; 5Ј-TTTTGCCACATAC (primer B for the intron-retention and primer C for the exon 9-skip-GCCTCACA-3Ј corresponding to position 1369 from the 5Јtransla-ping and the full-length cDNA) was incubated at 42ЊC for 60 min, tion region of SMN. heated to 65ЊC for 5 min, and quick-chilled on ice. PCR was performed at a final concentration of 1ϫ PCR buffer/0.2 mM dNTPs/ 0.5 M each 5Ј and 3Ј primers (primers A and B for the intronIn Situ Hybridization retention; primers A and C for the exon 9-skipping; primers D and
In situ hybridization was performed with digoxigenin-UTP-labeled C for the full length; Figure 1 )/2 U of Taq polymerase (Boehringer RNA probes generated from 1 g of DNA template using the MaxiMannheim)/2.5 l of reverse transcription reaction mixture in a total script in vitro transcription kit (Ambion, CA). The probes for detecting volume of 50 l. The mixture was overlaid with mineral oil and then wild-type EAAT2 mRNA and the partial intron 7-retention mRNA are amplified with the Delta Cycler II thermal cycler (Ericomp) for 25 or indicated in Figure 1 as probes E and F, respectively. Specificity 30 cycles. The amplification profile involved denaturation at 94ЊC controls included sense RNA probes and pretreatment of tissue for 30 s, primer annealing at 55ЊC for 30 s, and extension at 72ЊC
with RNase A (10 g/ml) in 2ϫ SSC at 37ЊC for 30 min. An actin for 1 min. PCR products (10 l) were resolved by 1.2% agarose gel control provided with the kit contained ‫052ف‬ bp of ␤-actin fragment electrophoresis and transferred to membrane. The blot was probed in the antisense orientation. Frozen tissue was sectioned (8 m), with a 32 P-labeled EAAT2 cDNA probe prepared by the random fixed with 4% paraformaldehyde in 0.1M phosphate buffered saline priming method (Figures 2A and 6 ) or a 32 P-end labeled oligonucleo-(PBS; pH 7.4), rinsed with PBS, treated with 0.2% Triton X-100, tide probe ( Figures 2B, 2C , 4A, and 4C) and then subjected to autorarinsed again with PBS followed by proteinase min, then rinsed with 0.1 M glycine in PBS, and again with 4% To screen for intron-retention mRNA, a plasmid (pE2F) was conparaformaldehyde in PBS. The sections were acetylated with 0.25% structed for use as an internal control for the comparative analysis acetic anhydride in TE with 0.1 triethanolamine, rinsed with DEPC of the intron-retention mRNA between patients. A 185 bp DNA fragwater, air dried, and then hybridized overnight with probe (2 ng/ml) ment with HindIII on both ends was inserted into the intronic mutant in hybridization buffer (50% deionized formamide, 5ϫ SSC, 10% cDNA at a HindIII site (indicated in Figure 1 , triangle). This plasmid, dextran sulfate, 5ϫ Denhardt solution, 2% SDS, 100 g/ml denapE2F, was used as a template for transcription by the T3 polymerase. tured salmon sperm DNA). The single-stranded RNA probe was The resulting pE2F complementary RNA (cRNA) product was puriremoved with RNase A (10 g/ml) at 37ЊC for 30 min. The immunologfied by oligo(dT) chromatography. Fifty nanograms of mRNA isolated ical detection of the digoxigenin-labeled RNA probe was performed from human tissue and 5 pg of cRNA were combined and then using alkaline phosphatase-conjugated anti-digoxigenin antibody reverse transcribed into cDNA by using primer B (Figure 1) . The (Boehringer Mannheim) at 1:200 and standard reagents for alkaline cDNA mixture was then amplified for 25 cycles. Under these condiphosphatase. tions, the reaction rates of pE2F cRNA and intron-retention mRNA were identical within an exponential phase of the PCR reaction.
In Vitro Expression and Construction Because the exon-skipping mRNA was 135 bp shorter than the wildof EAAT2-GFP Fusion Gene type EAAT2 mRNA, the wild-type EAAT2 mRNA was used as an Wild-type as well as aberrant cDNA fragments were cloned into a internal control for the comparative analysis of the exon-skipping eukaryotic expression vector (pcDNA3). The constructed plasmids mRNA between patients. Using the internal controls as standards, were then transfected into COS7 cells or HeLa cells by electroporathe relative amounts of intron-retention and exon 9-skipping mRNA tion. Electroporation (Bio Rad "Gene Pulser II", 300 V at 500 F) were calculated and compared, between patient samples, by densiwas performed on 1 ϫ 10 7 cells in a solution of DMEM containing tometric analysis of Southern blots. 500 g of salmon sperm DNA along with the pcDNA3 plasmid conFor CSF studies, 400 l CSF was centrifuged (1500 ϫ g) for 10
taining the transporter subtype. min to pellet blood cell debris. Total RNA was isolated from the For construction of the EAAT2-GFP fusion gene, wild-type or supernatant using QIAamp kit (Qiagen). Poly(A) mRNA was further aberrant EAAT2 cDNA in pcDNA3 was amplified by PCR using (ϩ) isolated and subjected to RT-PCR procedures as described above.
strand T7 primer and (Ϫ) strand primer (for wild-type and exon-EAAT2 is only expressed by CNS tissue. No wild-type or exon skipping mutant using 5Ј-GGATCCCGGGCCCTTTCTCACGTTTCCA 9-skipping EAAT2 mRNA was detected from the pelleted blood cell AGG-3Ј; for partial intron 7-retention species using 5Ј-GGATCCCG debris.
GGCCCCCTGGAAGCGGTGCCCAG-3Ј). To create a restriction site for cloning purposes, we added a 13 sequence (shown underlined) Cloning of PCR Products and Sequencing at the 5Ј ends of the primer to create ApaI. The resultant PCR PCR products were isolated from agarose gel by using QIAquick products were digested with EcoRI and ApaI and then cloned into Gel Extraction Kit (Qiagen). They were then cloned into a pCR 2.1 the N terminus of the GFP gene in pEGFP-N2 vector (Novagen). vector (TA Cloning Kit, Invitrogen). Plasmid DNA was isolated from Sequences of the chimeric genes were checked at their fusion sites. transformed cells by using PERFECT prep Plasmid DNA kit (5 prime → 3 prime, Inc.). Sequencing of the DNA was carried out on an Automated DNA Sequencer (Applied Biosystem). S1 Nuclease Protection Assay A 836 base single strand DNA probe was generated by asymmetry PCR using primers A and C. PCR conditions are the same as deOligonucleotides Primers used for RT-PCR of EAAT2 were as follows: Primer A (5Ј-scribed above, except 0.05 M primer A and 0.5 M primer C were used. The expected single strand DNA was isolated from the gel. GGCAACTGGGGATGTACA-3Ј) corresponding to position 933 from 5Ј translation region; Primer B (5Ј-CCAGAAGGCTCAAGAAGT-3Ј)
For hybridization and S1 nuclease analysis, 0.5 pmol of single strand DNA probe was mixed with 1 g of the mRNA sample and hybridized corresponding to position 170 from exon 7-intron junction; Primer in a solution containing 80% formamide, 0.4 M NaCl, 40 mM piperaBruijn, L.I., and Cleveland, D.W. (1996) . Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models zine-N,NЈ-bis (2-ethanesulfonic acid) (PIPES; pH 6.4), and 1 mM EDTA for 16 hr at 55ЊC. Samples were then diluted 15-fold with iceof motor neuron disease. Neuropathol. Appl. Neurobiol. 22, 373-387. cold S1 nuclease buffer (BRL) and treated with 0.5 U of S1 nuclease Campagne, M.V., Lucassen, P.J., Vermeulen, J.P., and Balazs, R. per microliter at 25ЊC for 1 hr. The protected fragments were re-(1995). NMDA and kainate induce internucleosomal DNA cleavage solved by 1.5% agarose gel electrophoresis and transferred to memassociated with both apoptotic and necrotic cell death in the neonabrane. The blot was probed with an oligonucleotide probe located tal rat brain. Eur. J. Neurosci. 7, 1627-1640. at the 3Ј end of the protection fragment (described above) and then Carriedo, S.G., Yin, H.-Z., Lamberta, R., and Weiss, J.H. (1995). subjected to autoradiography.
In vitro kainate injury to large, SMI-32(ϩ) spinal neurons is Ca 2ϩ dependent. Neuroreport 6, 945-948.
